Intra-articular injection of adipose-derived stromal vascular fraction in osteoarthritis of the temporomandibular joint

MCG0 sites40 target enrollmentTBD

Overview

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sponsor

MCG

•Age between 18\-70 years
•Chronic nociceptive pain in the TMJ region, aggravated by protrusion, maximal mouth opening, lateral excursions and/or chewing of at least 2 months
•Wilkes stages III or IV (internal derangement)
•Limited maximal interincisal opening (\< 35 mm and \> 15 mm)
•Pain still present after two weeks of a NSAID (i.e. ibuprofen 600 mg three times daily, or diclophenac 50 mg 3td, or napoxen 500 mg 2 td)
•Pain disappears after diagnostic intra\-articular injection

•Edentulous (no dentition)
•Previous treatments acting on cartilage or bone metabolism (eg, oral or intravenous bisphosphonates \<1 year previously, strontium ranelate or teriparatide or raloxifene \<7 days prior to selection, and oral glucosamine \=1500 mg/day and chondroitin sulphate \<3 months previously)
•Concurrent use of anti\-inflammatory medication, steroids, muscle relaxants or antidepressants
•Previous TMJ traumas and fractures
•Previous TMJ surgeries, previous intra\-articular injections \< 1 year before
•Bilateral severe TMJ derangements
•Bony or fibrotic ankylosis of the TMJ
•Known history of diabetes mellitus type 1 or 2
•Known history of HIV
•Serious systemic diseases, rheumatic disease or infectious/inflammatory diseases affecting the skin of the area of the TMJ